Kinnate Biopharma Q3 FY21: net loss $24.7M; diluted EPS −$0.57

Key figures from this report

These are the numbers Kinnate Biopharma reported for Q3 FY21, the quarter ended Sep 30, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$24.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Diluted EPS−$0.57No year-earlier figure tagged10-Q income statement, on EDGAR
3. Cash and cash equivalents$135.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$17.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters